Husker research duo selected as Phase 1 winners in the NIH's Targeted Genome Editor ...

Retrieved on: 2024-02-19 17:09:54

Tags for this article:

Genetic engineering

Biotechnology

Extracellular vesicle

CRISPR

Cas9

Insulin-degrading enzyme

Jiantao Guo

Click the tags to see associated articles and topics

Husker research duo selected as Phase 1 winners in the NIH's Targeted Genome Editor .... View article details on HISWAI: https://www.news-medical.net/news/20240219/Husker-research-duo-selected-as-Phase-1-winners-in-the-NIHs-Targeted-Genome-Editor-Delivery-Challenge.aspx

Summary

The University of Nebraska-Lincoln researchers, Janos Zempleni and Jiantao Guo, won an NIH award for developing milk exosomes as a biotechnology platform to deliver CRISPR-Cas9 genome editors for treating various diseases. Their work brings together genetic engineering, molecular biology, and advances in exosome technology for gene therapy applications.

Article found on: www.news-medical.net

View Original Article